US FDA approves two gene therapies for sickle cell disease

The US Food and Drug Administration (FDA) has approved two gene therapies for sickle cell disease, including the first treatment in the US based on CRISPR gene editing technology. Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, and bluebird bio's Lyfgenia were approved for people aged 12 years and older.
Source: The Economic Times - Category: Consumer Health News Source Type: news